FT. LAUDERDALE, FL -- (MARKET WIRE) -- April 02, 2007 -- OmniComm Systems, Inc. (OTCBB: OMCM), one of the fastest growing companies in the EDC marketplace, today announced that Cardium Therapeutics of San Diego, CA has selected the TrialMaster EDC solution for conducting a Phase 3 study in women which will evaluate Generx™ (alferminogene tadenovec) as a potential treatment for myocardial ischemia (insufficient blood flow within the heart muscle).
